Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

Efficacy of PTCy after mismatched unrelated donor (MMUD) HCT is unknown. In this pilot clinical trial, we enrolled 38 patients with hematologic malignancies scheduled to undergo MMUD-HCT (≥6/8 HLA-matched donors) onto 1 of 2 conditioning strata: myeloablative using fludarabine and fractionated total...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Al Malki, Monzr M., Tsai, Ni-Chun, Palmer, Joycelynne, Mokhtari, Sally, Tsai, Weimin, Cao, Thai, Ali, Haris, Salhotra, Amandeep, Arslan, Shukaib, Aldoss, Ibrahim, Karras, Nicole, Karanes, Chatchada, Zain, Jasmine, Khaled, Samer, Stein, Anthony, Snyder, David, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2021
Assuntos:
Transplantation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270662/
https://ncbi.nlm.nih.gov/pubmed/34156440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004192
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares